home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

108.89 -1.53 (-1.39%)

Streaming Delayed Price Updated: 10:35 AM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

71 72 Next >

Moderna Has Lost 94% Of Its Value Over Four Years. Is It A Sell? ↗

January 14, 2025

Shares hit another skid on Jan. 13 when the company cut its guidance for 2024 and 2025.

Via Investor's Business Daily

BioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference

January 14, 2025

From BioNTech SE

Via GlobeNewswire

Why BioNTech (BNTX) Shares Are Volatile Today ↗

January 13, 2025

Shares of BioNTech fell 4% on Monday. Vaccine stocks are volatile after Moderna's updated revenue guidance for 2025, which fell below analyst expectations.

Via Benzinga

BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst ↗

January 10, 2025

Truist rates BioNTech a Buy, citing its shift to oncology with BNT327 leading the way. Key data updates and growth catalysts are expected by 2025.

Via Benzinga

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗

January 09, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Via Investor's Business Daily

Topics Artificial Intelligence Government

Critical Insights From BioNTech Analyst Ratings: What You Need To Know ↗

December 11, 2024

Via Benzinga

Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside ↗

January 07, 2025

Jefferies upgrades Instil Bio to "Buy" with a $52 target, anticipating significant growth for PD-(L)1xVEGF class and SYN2510's potential in cancer treatments.

Via Benzinga

Moderna, BioNTech, Novavax Surge After CDC Reports Two-Week Covid Spike ↗

January 07, 2025

Moderna, BioNTech and Novavax stocks popped after the CDC noted a recent increase in positive Covid tests.

Via Investor's Business Daily

5 Predictions for the Stock Market in 2025 -- and Which Stocks Will Soar the Most If They're Right ↗

January 04, 2025

Via The Motley Fool

Pfizer Sets Up For A Wild Ride In 2025 Amid Looming Threats From Starboard, Kennedy ↗

December 18, 2024

Pfizer stock is setting up for a wild ride in 2025 as it faces off with an activist and, possibly, Robert F. Kennedy Jr. at HHS.

Via Investor's Business Daily

3 No-Brainer Biotech Stocks to Buy With $200 Right Now ↗

December 18, 2024

Via The Motley Fool

The Analyst Landscape: 17 Takes On BioNTech ↗

November 14, 2024

Via Benzinga

What Analysts Are Saying About BioNTech Stock ↗

November 08, 2024

Via Benzinga

Breaking Down BioNTech: 16 Analysts Share Their Views ↗

November 06, 2024

Via Benzinga

2 Healthcare Stocks to Buy Hand Over Fist and 1 to Avoid ↗

December 11, 2024

Via The Motley Fool

2 No-Brainer Stocks to Buy Before the End of 2024 ↗

December 09, 2024

Via The Motley Fool

Why Is BioNTech Stock Trading Higher On Friday? ↗

December 06, 2024

BNT324/DB-1311 trial data show significant antitumor activity in various cancers, with high response rates in small cell lung and prostate cancer patients.

Via Benzinga

5 Top Stocks to Buy in December ↗

December 04, 2024

Take a closer look at these bargain-bin value stocks, quality dividend stocks, and one scorching-hot growth stock.

Via The Motley Fool

This BioNTech Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗

November 19, 2024

Via Benzinga

Powell Speaks The Truth - Market Does Not Like It, Consternation About Kennedy, Gaetz, And Hegseth ↗

November 15, 2024

To gain an edge, this is what you need to know today.

Via Benzinga

European And US Vaccine Stocks Are Under Pressure - Here's WHy ↗

November 15, 2024

Vaccine stocks react to Robert F. Kennedy Jr.'s HHS nomination. FDA and NIH express concerns over his anti-vaccine views amid market shifts.

Via Benzinga

Pfizer, Moderna, Novavax Take A Beating After Trump Taps Kennedy To Head Up HHS ↗

November 15, 2024

President-elect Donald Trump tapped widely known vaccine skeptic Robert F. Kennedy Jr. to lead the Department of Health and Human Services.

Via Investor's Business Daily

Topics Government

BioNTech Stock Got A IBD RS Rating Lift ↗

November 14, 2024

A Relative Strength Rating upgrade for BioNTech ADR shows improving technical performance.

Via Investor's Business Daily

BioNTech Boosts Oncology Strategy With $800 Million+ China-Based Biotheus Acquisition ↗

November 13, 2024

BioNTech acquires Biotheus for $800 million plus milestone payments, securing global rights to BNT327/PM8002 and expanding its oncology and R&D presence in China.

Via Benzinga

BioNTech to Acquire Biotheus to Boost Oncology Strategy

November 13, 2024

From BioNTech SE

Via GlobeNewswire

BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential ↗

November 09, 2024

Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future revenue amid shifting company focus.

Via Benzinga

This Bank of America Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday ↗

November 08, 2024

Via Benzinga

Trump's Potential 'Health Czar' Robert F. Kennedy Jr. Rattles Vaccine Stocks: 'Shoot First Reaction' ↗

November 07, 2024

Donald Trump has said he will give Robert F. Kennedy Jr. a senior role in his incoming administration to advance his "Make America Healthy Again" agenda.

Via Benzinga

Topics Government

BioNTech Se (BNTX) Q3 2024 Earnings Call Transcript ↗

November 04, 2024

BNTX earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

BioNTech Variant-adapted COVID-19 Vaccines Do Well In Q3 ↗

November 04, 2024

BioNTech's Q3 revenue surged to €1.244 billion, reflecting early COVID-19 vaccine approvals. Net profit rose to €198.1 million, and full-year guidance adjusted downward.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

71 72 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com